Edouard L. Fu

Dec 18, 2024 | ejves.com | Shigeru Tanaka |Alessandro Bosi |Edouard L. Fu |Kunitoshi Iseki |Takanari Kitazono |Rebecka Hultgren | +2 more

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes Full length articleArticles in PressOpen access aDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden bDepartment of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan...

Jul 3, 2023 | pubmed.ncbi.nlm.nih.gov | Safia Chatur |Edouard L. Fu |Muthiah Vaduganathan

Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software

Jun 1, 2023 | jacc.org | Safia Chatur |Edouard L. Fu |Muthiah Vaduganathan

JACC Journals › JACC: CardioOnc › Archives › Vol. 5 No. 3 IntroductionOver the last decade, advances in cancer care have dramatically improved the longevity of patients with various cancers. However, cardiotoxicity including the development of arrhythmias, thrombotic complications, subclinical cardiac dysfunction, and clinical heart failure (HF) remains a major impediment to the broader use of potentially life-saving cancer therapies such as anthracyclines.